{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T01:32:22Z","timestamp":1780882342037,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11910-019-0982-3","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T07:02:48Z","timestamp":1565247768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Updates in the Diagnosis and Management of Giant Cell Arteritis"],"prefix":"10.1007","volume":"19","author":[{"given":"Surabhi","family":"Uppal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Chhaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"982_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/ICU.0b013e32833eae8b","volume":"21","author":"N Kale","year":"2010","unstructured":"Kale N, Eggenberger E. Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol. 2010;21:417\u201322.","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"982_CR2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454\u201361.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"982_CR3","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","volume":"72","author":"TA Kermani","year":"2013","unstructured":"Kermani TA, Warrington KT, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989\u201394.","journal-title":"Ann Rheum Dis"},{"key":"982_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/BOR.0b013e32833ee946","volume":"23","author":"CM Weyand","year":"2011","unstructured":"\u2022 Weyand CM, Younge BR, Goronzy JJ. IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43\u20139 This paper has a description of some additional potential mechanisms of pathophysiology of GCA which then can be used as targets for management of disease.","journal-title":"Curr Opin Rheumatol"},{"key":"982_CR5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/j.2326-5205.1989.tb00020.x","volume":"32","author":"MC Cid","year":"1989","unstructured":"Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum. 1989;32:884\u201393.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"982_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, Goronzy JT, Weyand CM. Th17 abd Th1 responses in giant cell arteritis. Circulation. 2010;121(7):906\u201315.","journal-title":"Circulation"},{"issue":"6","key":"982_CR7","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/art.34327","volume":"64","author":"B Terrier","year":"2012","unstructured":"Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, et al. Interleukin 21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 2012;64(6):2001\u201311.","journal-title":"Arthritis Rheum"},{"key":"982_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","volume":"33","author":"JA Dudakov","year":"2015","unstructured":"Dudakov JA, Hanash AM, van den Brink MR. Interleukin 22: immunology and pathology. Annu Rev Immunol. 2015;33:747\u201385.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"982_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/QCO.0000000000000258","volume":"29","author":"D Gilden","year":"2016","unstructured":"\u2022 Gilden D, Nagel MA. Varicella zoster virus and giant cell arteritis. Curr Opin Infect Dis. 2016;29(3):275\u20139 This article discusses the possible role of VZV in triggering the immunopathology of GCA and the role of antivirals in treatment.","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"982_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/BOR.0000000000000292","volume":"28","author":"D Gilden","year":"2016","unstructured":"Gilden D, Nagel A. Varicella zoster virus triggers the immunopathology of giant cell arteritis. Curr Opin Rheumatol. 2016;28(4):376\u201382.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"982_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","volume":"36","author":"C Font","year":"1997","unstructured":"Font C, Cid MC, Coll-Vincent B, L\u00f3pez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy proven giant cell arteritis. Br J Rheumatol. 1997;36(2):251\u20134.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"982_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","volume":"79","author":"MA Gonz\u00e1lez-Gay","year":"2000","unstructured":"Gonz\u00e1lez-Gay MA, Garcia-Porr\u00faa C, Llorca J, Hajeer AH, Bra\u00f1as F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine. 2000;79(5):283\u201392.","journal-title":"Medicine"},{"issue":"4","key":"982_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0889-857X(05)70235-0","volume":"27","author":"NR Miller","year":"2001","unstructured":"Miller NR. Visual manifestations of temporal arteritis. Rheum Dis Clin N Am. 2001;27(4):781\u201397.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"982_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0002-9394(99)80192-5","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509\u201320.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"982_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","volume":"84","author":"MA Gonzalez-Gay","year":"2005","unstructured":"Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine. 2005;84(5):269\u201376.","journal-title":"Medicine"},{"issue":"1","key":"982_CR16","first-page":"93","volume":"22","author":"SE Gabriel","year":"1995","unstructured":"Gabriel SE, O\u2019Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol. 1995;22(1):93\u20136.","journal-title":"J Rheumatol"},{"key":"982_CR17","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/art.11480","volume":"48","author":"DM Nuenninghoff","year":"2003","unstructured":"Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532\u20137.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"982_CR18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2011-200865","volume":"71","author":"S Prieto-Gonz\u00e1lez","year":"2012","unstructured":"Prieto-Gonz\u00e1lez S, Arguis P, Garc\u00eda-Mart\u00ednez A, Esp\u00edgol-Frigol\u00e9 G, Tavera-Bahillo I, Butj\u00f2sa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis:prospective study in 4 newly diagnosed patients using GT angiography. Ann Rheum Dis. 2012 Jul;71(7):1170\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6\u20137","key":"982_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.autrev.2012.01.003","volume":"11","author":"AT Borchers","year":"2012","unstructured":"Borchers AT, Gershwin ME, et al. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11(6\u20137):544\u201354.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"982_CR20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3899\/jrheum.080792","volume":"36","author":"GS Breuer","year":"2009","unstructured":"Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009;36(4):794\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"982_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcjo.2013.12.008","volume":"49","author":"B Durling","year":"2014","unstructured":"Durling B, Toren A, Patel V, Gilberg S, Weis E, Jordan D. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol. 2014;49(2):157\u201361.","journal-title":"Can J Ophthalmol"},{"key":"982_CR22","doi-asserted-by":"crossref","unstructured":"\u2022 Jakobsson K, Jacobsson L, Mohammad AJ, Nilsson J\u00c5, Warrington K, Matteson EL, et al. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskelet Disord. 2016;17(1):\u2013363 This article addresses the common and clinically relevant question regarding whether steroids should be started prior to a temporal artery biopsy.","DOI":"10.1186\/s12891-016-1225-2"},{"key":"982_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2474-11-44","volume":"11","author":"A Arida","year":"2010","unstructured":"Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010;11:44.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"982_CR24","doi-asserted-by":"publisher","first-page":"e000612","DOI":"10.1136\/rmdopen-2017-000612","volume":"4","author":"C Duftner","year":"2018","unstructured":"Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4(1):e000612.","journal-title":"RMD Open"},{"issue":"1","key":"982_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/art.21699","volume":"55","author":"D Blockmans","year":"2006","unstructured":"Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006 Feb;55(1):131\u20137.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"982_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/03009742.2016.1190984","volume":"46","author":"N Naderi","year":"2017","unstructured":"Naderi N, Mohammad AJ, Turesson C. Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution and predictors. Scand J Rheumatol. 2017;46(3):215\u201321.","journal-title":"Scand J Rheumatol"},{"key":"982_CR27","doi-asserted-by":"crossref","unstructured":"De Boysson H, Lambert M, Liozon E, Boutemy J, Maign\u00e9 G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: working diagnosis of a distinct disease pattern. Medicine. 2016;95(26).","DOI":"10.1097\/MD.0000000000003818"},{"issue":"4","key":"982_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"\u2022 Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheum. 2017;69(4):837 This article discusses another alternative to steroids for the treatment of GCA.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"982_CR29","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","volume":"75","author":"R Conway","year":"2016","unstructured":"Conway R, O'Neill L, O'Flynn E, Gallagher P, McCarthy GM, Murphy CC, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"982_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M De Silva","year":"1986","unstructured":"De Silva M, Hazleman BL. Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"982_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semarthrit.2012.12.023","volume":"43","author":"H de Boysson","year":"2013","unstructured":"de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105.","journal-title":"Semin Arthritis Rheum"},{"key":"982_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","volume":"38","author":"A Hocevar","year":"2019","unstructured":"Hocevar A, Jese R, Rotar Z, Tomsic M. Does leflunomide have a role in giant cell arte`ritis? An open label study. Clin Rheumatol. 2019;38:291.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"982_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621.","journal-title":"Ann Intern Med"},{"issue":"12","key":"982_CR34","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Pu\u00e9chal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"982_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"VM Mart\u00ednez-Taboada","year":"2008","unstructured":"Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Carre\u00f1o L, L\u00f3pez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"982_CR36","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"982_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","volume":"37","author":"B Bienvenu","year":"2016","unstructured":"\u2022 Bienvenu B, Ly KH, Lambert M, Agard C, Andr\u00e9M BY, Bonnotte B, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016;37(3):154 This article is significant for recommendations on the management of GCA with corticosteroids.","journal-title":"Rev Med Interne"},{"issue":"3","key":"982_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"982_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/ard.47.9.733","volume":"47","author":"G Delecoeuillerie","year":"1988","unstructured":"Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47(9):733.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"982_CR40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/ard.48.8.662","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989;48(8):662.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"982_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.12998\/wjcc.v3.i6.484","volume":"3","author":"C Ponte","year":"2015","unstructured":"Ponte C, Rodriguez AF, O\u2019Neill L, Luqmani RA. Giant cell arteritis:current treatment and management. World J Clin Cases. 2015;3(6):484\u201394.","journal-title":"World J Clin Cases"},{"issue":"6","key":"982_CR42","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. Agron a randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484.","journal-title":"J Rheumatol"},{"key":"982_CR43","doi-asserted-by":"crossref","unstructured":"Tsalapaki C, Lazarini A, Antonatou K, Thomas K, Klavdianou K, Koutsianas C, et al. Frequency of relapses and treatment discontinuation during long-term follow-up of patients with giant cell arteritis. Ann Rheum Dis. 2017;76(sup 2):321\u20131.","DOI":"10.1136\/annrheumdis-2017-eular.6115"},{"issue":"5","key":"982_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"982_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hern\u00e1ndez-Garc\u00eda C, Morado IC, Vargas E, Ba\u00f1ares A, Fern\u00e1ndez-Guti\u00e9rrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106.","journal-title":"Ann Intern Med"},{"issue":"5","key":"982_CR46","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495\u2013501.","journal-title":"Clin Exp Rheumatol"},{"issue":"2 Supp","key":"982_CR47","first-page":"435","volume":"77","author":"IM Henry","year":"2018","unstructured":"\u2022 Henry IM, Coronel L, Casta\u00f1o I, Peiteado D, Garc\u00eda-Carazo S, Balsa A, et al. THU0447 No advantage of methotrexate in the treatment of giant cell arteritis. Ann Rheum Dis. 2018;77(2 Supp):435 This addresses the effect of using Methotrexate as a steroid sparing agent in GCA which is commonly done in clinical practice.","journal-title":"Ann Rheum Dis"},{"key":"982_CR48","first-page":"1192","volume":"39","author":"C Richez","year":"2012","unstructured":"Richez C, Barnetche T, Khoryati L, et al. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Respir Dis. 2012;39:1192\u20137.","journal-title":"J Respir Dis"},{"key":"982_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJ. Clinical practice: giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50\u20137.","journal-title":"N Engl J Med"},{"key":"982_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","volume":"5","author":"A Rubbert-Roth","year":"2018","unstructured":"\u2022 Rubbert-Roth A, Furst DE, Nebesky JM, et al. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5:21\u201342 This article discusses the use of an effective steroid sparing agent for GCA.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"982_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/acr.21569","volume":"64","author":"M Durand","year":"2012","unstructured":"Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res. 2012 Apr;64(4):581\u20138.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"982_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.20435","volume":"63","author":"TA Kermani","year":"2011","unstructured":"Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jirovecii pneumonia in giant cell arteritis: a case series. Arthritis Care Res. 2011;63(5):761\u20135.","journal-title":"Arthritis Care Res"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-0982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-019-0982-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-0982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T20:17:25Z","timestamp":1721593045000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-019-0982-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s11910-019-0982-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"assertion":[{"value":"8 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Surabhi Uppal, Mohanad Hadi, and Sheetal Chhaya each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"68"}}